VIVA动态丨维亚生物与NanoImaging Services达成战略合作协议，打造从基因到结构的冷冻电镜一体化服务- 大数跨境

VIVA动态丨维亚生物与NanoImaging Services达成战略合作协议，打造从基因到结构的冷冻电镜一体化服务

维亚生物

2021-10-12

导读：本次合作将结合双方在结构解析及冷冻电镜方面的技术优势，进一步赋能针对复杂结构的药物研发项目。

上海，圣迭戈——近日，维亚生物科技控股集团（1873.HK）（以下简称“维亚生物”）与NanoImaging Services, Inc（以下简称“NIS”）宣布达成战略合作协议，双方将基于冷冻电镜技术展开合作，为客户提供从基因到结构解析的一体化服务。

根据合作协议，客户可同时使用维亚生物和NIS的研发资源，完成从蛋白质构建设计到最终图谱，及后续蛋白质供应和药物化学环节。这将有利于缺乏蛋白科学和冷冻电镜技术及基础设备的研发企业，进行复杂靶点的解析和结构验证。

维亚生物执行董事兼总裁任德林博士表示：“很高兴与NIS达成战略合作。我们双方的技术平台具有显著的协同增益作用。NIS作为世界顶尖的冷冻电镜服务提供商，在结构解析技术与电镜设备领域具备充足优势。结合维亚生物高效的蛋白表达生产能力，以及专有的膜蛋白表达与筛选技术，本次合作将有望进一步赋能全球创新药客户，提升研发效率，造福更多患者。”

NIS首席商务官Ben Schenker表示：“通过整合双方的技术优势及过往的成功案例经验，相信本次合作可有效提升靶点开发和药物化学的研发效率，并提高研发的成功率，从而降低整体研发投入。”

“基于结构的药物发现成功的关键因素在于试剂的纯度、均一性及深入的生物化学和生物物理鉴定”，NIS首席科学家Giovanna Scapin博士表示，“此次合作协议汇集双方的优势，维亚生物是蛋白生产领域的全球领先者，而NIS在冷冻电镜高分辨率结构解析方面具备行业领先的专业性及高度创新性。我们致力于为客户在复杂及具备挑战性的药物研发项目上提供低成本、高效率的解决方案。”

关于NanoImaging Services

NIS成立于2007年，专注于为制药企业、生物科技公司及纳米技术公司提供成像服务，矢志打造一个专业的、可靠的及协作的以客户为中心的组织，致力于通过显微采集、工作流程自动化、顶尖人才的招聘和培训及新产品新服务的开发来提升公司的服务能力。NIS最先进的设备包括一系列电子显微镜、样品制备设备及计算机相关的基础设施以支持结构生物学、纳米颗粒分析和化学工作流程。在完成最近的收购后，NIS已发展成为生命科学市场上规模最大、最全面的TEM, cryoEM 和 microED服务商之一。

更多信息访问 www.nanoimagingservices.com/about-us/our-company

Shanghai, San Diego ——

Viva Biotech Holdings (1873.HK) and NanoImaging Services, Inc. recently announced a new partnership agreement that will provide clients with a streamlined, cryoEM enabled gene to structure workflow.

Under the terms of the collaboration, clients can access the pooled resources of both companies under a single agreement to manage their projects from construct design through to final maps and subsequent protein supply and analyses for medicinal chemistry cycles. This will facilitate target and structure validation for companies with challenging targets that lack protein science and/or cryo-EM expertise and infrastructure.

“We are very excited to build the strategic cooperation with NIS. Viva and NIS will achieve great synergies. As the world's top cryo-EM service provider, NIS has considerable advantages in technology and equipment. As the world's leading drug discovery platform, Viva has efficient protein purification and production capabilities, along with the advanced membrane protein expression and screening technology. Our cooperation is expected to further enhance the ability of target discovery, to empower the clients to develop new drugs as soon as possible, and benefit more patients.” said Dr. Ren Delin, Executive Director and President of Viva.

“By combining forces and aligning already successful and proven workflows, we believe target enablement and medicinal chemistry timelines can be shortened significantly and success rates increased, bringing down the overall investment costs.” said Ben Schenker, Chief Commercial Officer at NanoImaging Services.

“It is clear that one of the strongest predictors of success in structural enablement of drug discovery targets is the purity, homogeneity, and in-depth biochemical and biophysical characterization of the reagents involved”, said Giovanna Scapin, Ph.D., Chief Scientific Officer at NIS. “This new collaborative agreement brings together a worldwide leader in protein production and characterization with our industry-leading expertise and innovation in high-resolution structural enablement by cryo-EM. Together we aim to successfully target the most complex and challenging projects in drug discovery for our shared clients in a cost- and time- effective manner.”

About NanoImaging Services

NIS launched in 2007 to provide imaging services to the pharmaceutical, biotechnology and nanotechnology communities. We have since built a client-focused organization with a reputation for expertise, reliability and collaboration. NIS is committed to expanding our service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and the development of new service offerings. Our state-of-the-art facilities include a range of electron microscopes, sample preparation equipment and computational infrastructure to support structural biology, nanoparticle characterization and chemistry workflows. With recent acquisitions, NIS has become the largest and most comprehensive provider of TEM, cryoEM and microED services to the industrial life science market.

Visit www.nanoimagingservices.com/about-us/our-company.

【声明】内容源于网络

维亚生物

维亚生物作为全球知名的一站式药物研发及生产平台，专注于提供从早期基于结构的药物研发到商业化药物交付的一站式综合服务，致力于成为全球创新型生物研发公司长期的合作伙伴。

内容 0

粉丝 0

维亚生物维亚生物作为全球知名的一站式药物研发及生产平台，专注于提供从早期基于结构的药物研发到商业化药物交付的一站式综合服务，致力于成为全球创新型生物研发公司长期的合作伙伴。

总阅读0

粉丝0

内容0